Sonoma Pharmaceuticals Reports Fiscal Year and Fourth Quarter 2026 Financial Results

Revenues increased 48% in Q4 2026 compared to Q4 2025, and 37% in FY 2026 compared to FY 2025United States revenues increased 194% in Q4 2026 compared to Q4 2025 and 117% in FY 2026 compared to FY 2025Net loss improved 25% in Q4 2026 compared to Q4 …